Kulkarni Samarth 4
4 · CRISPR Therapeutics AG · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
CRISPR Therapeutics (CRSP) CEO Samarth Kulkarni Sells Shares
What Happened Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), reported conversion/exercise of derivative awards and a subsequent sale. The Form 4 shows a conversion/exercise of 13,250 derivative units on Feb 18, 2026, and an open-market sale of 6,967 shares on Feb 19, 2026 at $52.58 each, generating proceeds of $366,325. The filing also reports a same-day derivative disposition of 13,250 units (see Key Details for notes).
Key Details
- Filing date / Period of report: Filed 2026-02-20 for transactions on 2026-02-18 and 2026-02-19 (filed within the typical 2-business-day window).
- Transactions:
- 2026-02-18: Exercise/conversion of derivative (code M) — 13,250 shares (acquired).
- 2026-02-18: Disposition of 13,250 derivative units (code M) — reported as disposed.
- 2026-02-19: Open-market sale (code S) — 6,967 shares at $52.58 each = $366,325 total.
- Shares owned after transaction: Not specified in the supplied excerpt of the filing.
- Footnotes of note:
- F1: Each RSU converts to one common share.
- F3: The 6,967-share sale reflects shares sold to cover tax withholding on vesting (mandated by the company’s RSU Settlement Policy) — not a discretionary sale.
- F2/F4: Filing reflects prior transfers (85,622 shares from a 2023 GRAT) and the RSU award granted Feb 18, 2022 that vested in quarterly tranches culminating on Feb 18, 2026.
Context
- The filing indicates conversion/exercise of derivative awards concurrent with RSU vesting; part of the resulting shares were sold to meet tax withholding obligations (per company policy), which is routine and non-discretionary.
- Sales to cover taxes or withholding are common after vesting and do not necessarily signal management’s view of the stock.
Insider Transaction Report
Form 4
Kulkarni Samarth
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Shares
[F1][F2]2026-02-18+13,250→ 233,073 total - Sale
Common Shares
[F3]2026-02-19$52.58/sh−6,967$366,325→ 226,106 total - Exercise/Conversion
Restricted Stock Units
[F1][F4]2026-02-18−13,250→ 0 total→ Common Shares (13,250 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Reflects 85,622 shares previously transferred from the Kulkarni 2023 GRAT to the Reporting Person.
- [F3]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F4]This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
Signature
/s/ Samarth Kulkarni|2026-02-20